Business
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
Jefferies Gene Therapy & Editing Summit on October 28 at 11:00 am ET DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nJefferies Gene Therapy & Editing Summit on October 28 at 11:00 am ET\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at the Jefferies Gene Therapy & Editing Summit.\n\nConference Details:\n\n\n\nEvent:\n\n\n\n\nJefferies Gene Therapy & Editing Summit\n\n\n\n\n\nDate:\n\n\n\n\nThursday, October 28, 2021\n\n\n\n\n\nTime:\n\n\n\n\n11:00 am ET\n\n\n\n\n\nFormat:\n\n\n\n\nFireside Chat\n\n\n\n\n\nParticipants:\n\n\n\n\nRA Session II, President, Founder and Chief Executive Officer\n\n\n\n\n\n \n\n\n\n\nDr. Suyash Prasad, Chief Medical Officer and Head of R&D\n\n\n\n\n\n \n\n\n\n\nKamran Alam, Chief Financial Officer\n\n\n\n\n\n \n\n\n\n\nDr. Kimberly Lee, SVP, Corporate Communications and Investor Relations\n\n\n\n\nAbout Taysha Gene Therapies\n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20211021005262/en/\n\nCompany Contact:\nKimberly Lee, D.O.\nSVP, Corporate Communications and Investor Relations\nTaysha Gene Therapies\[email protected]\n\nMedia Contact:\nCarolyn Hawley\nCanale Communications\[email protected]\n\nSource: Taysha Gene Therapies, Inc.","length":6697,"tagName":"div"}]